<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638820</url>
  </required_header>
  <id_info>
    <org_study_id>0704M06581</org_study_id>
    <secondary_id>MT2007-06</secondary_id>
    <nct_id>NCT00638820</nct_id>
  </id_info>
  <brief_title>Reduced Intensity AlloTransplant For Osteopetrosis</brief_title>
  <official_title>Reduced Intensity Allogeneic Transplantation For Severe Osteopetrosis Incorporating A Second Cd34 Selected Graft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We believe that hematopoietic stem cell transplantation (HSCT) will help subjects with
      Osteopetrosis generate functioning osteoclasts, and by so doing assist in the resolution of
      the abnormal bone architecture, and the anemia and bone marrow failure that is also
      characteristic of this disease. However, we have found in past studies that approximately 30%
      of Osteopetrosis patients do not engraft. Therefore, in this study, we plan to use a
      different combination of pre-transplant drugs to try to make transplants safer for this
      disease, as well as to provide a second infusion of stem cells in patients with matched
      related or unrelated donors. The purpose of this research is to find a safer and more
      effective means of performing stem cell transplantation in patients with Osteopetrosis, using
      chemotherapy and radiation designed to bring about engraftment and lessen transplant
      mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This transplant protocol will test the following: 1) the ability to achieve engraftment with
      the reduced intensity protocol, 2) the mortality associated with transplant by day 100, 3)
      patient outcomes, based on differential imaging and biologic evaluations prior to
      transplantation and at designated points after transplantation (day 100, 6 months, 1, 2 and 5
      years). Additional biologic studies will include microarray analysis, Campath levels just
      prior to the administration of the graft, and establishment of mesenchymal stem cell lines.
      In older patients, studies to evaluation osteoclast differentiation and function will also be
      offered.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Excess toxicity
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Achieving Donor Cell Engraftment</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of patients with persistent presence of donor-derived cells at Day 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Transplant Related Death</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of participants died during study by Day 100 and reason for death was related to transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Transplant Related Toxicity</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of patients experiencing adverse effects due to transplant categorized by body system using Common Terminology Criteria for Adverse Events coding from the National Cancer Institute, Version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differential Imaging and Biologic Evaluations</measure>
    <time_frame>Day 100, 6 months, 1, 2 and 5 years</time_frame>
    <description>These outcome measures were not assessed due to early study termination.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Osteopetrosis</condition>
  <arm_group>
    <arm_group_label>Intent-To-Treat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled and received study treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell or Umbilical Cord Blood Transplantation</intervention_name>
    <description>Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42</description>
    <arm_group_label>Intent-To-Treat</arm_group_label>
    <other_name>Bone Marrow Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath, Busulfan, Clofarabine</intervention_name>
    <description>12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours
11 Campath-1H 0.3 mg/kg intravenously over 2 hours
10 Campath-1H 0.3 mg/kg intravenously over 2 hours
9 Busulfan &lt;12 kg: 2.2 mg/kg/dose IV every 12 hours &gt;12 kg: 1.6 mg/kg/dose IV every 12 hours
8 Busulfan &lt;12 kg: 2.2 mg/kg/dose IV every 12 hours &gt;12 kg: 1.6 mg/kg/dose IV every 12 hours
7 &quot;Rest&quot;
6 Clofarabine 40 mg/m2 intravenously over 2 hours
5 Clofarabine 40 mg/m2 intravenously over 2 hours
4 Clofarabine 40 mg/m2 intravenously over 2 hours
3 Clofarabine 40 mg/m2 intravenously over 2 hours
2 Clofarabine 40 mg/m2 intravenously over 2 hours</description>
    <arm_group_label>Intent-To-Treat</arm_group_label>
    <other_name>Busulfex, Clolar,Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Lymphoid Irradiation</intervention_name>
    <description>Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).</description>
    <arm_group_label>Intent-To-Treat</arm_group_label>
    <other_name>Therapuetic radation, radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients eligible for transplantation under this protocol will be &lt;45 years of age,
             and will be diagnosed with severe osteopetrosis. This will be defined as having the
             following manifestations of the disease.

          -  Bones that are uniformly markedly dense based on skeletal survey

          -  No history that would suggest autosomal dominant inheritance

          -  Evidence of hematologic changes that are attributed to the underlying disease,
             including the need for ongoing transfusions, OR

          -  the presence of progressive anemia or thrombocytopenia, OR a white blood cell
             differential with a predominance of immature forms and evidence of extramedullary
             hematopoiesis, OR

          -  persistence of serious infectious complications that are thought to be due to the
             abnormal architecture of the bone that are resistant to surgical and medical
             interventions.

        Exclusion Criteria:

          -  Patients &gt;45 years of age

          -  Evidence of hepatic failure

          -  pulmonary dysfunction sufficient to substantially increase the risk of transplant

          -  Renal dysfunction with glomerular filtration rate (GFR) &lt;30% of predicted.

          -  Cardiac compromise sufficient to substantially increase the risk of transplantation

          -  Severe, stable neurologic impairment.

          -  Human immunodeficiency virus (HIV) positivity.

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Orchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of MInnesota, Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <results_first_submitted>August 26, 2009</results_first_submitted>
  <results_first_submitted_qc>January 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2010</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <name_title>Paul Orchard, M.D.</name_title>
    <organization>University of Minnesota</organization>
  </responsible_party>
  <keyword>osteopetrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteopetrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study was terminated early due to stopping rules. The first 3 patients enrolled died by Day 100 of study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients With Osteopetrosis Who Received Transplant</title>
          <description>All patients enrolled with osteopetrosis and received transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Osteopetrosis Who Received Transplant</title>
          <description>All patients enrolled with osteopetrosis and received transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Achieving Donor Cell Engraftment</title>
        <description>Number of patients with persistent presence of donor-derived cells at Day 100</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Osteopetrosis Who Received Transplant</title>
            <description>All patients enrolled with osteopetrosis and received transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Donor Cell Engraftment</title>
          <description>Number of patients with persistent presence of donor-derived cells at Day 100</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Transplant Related Death</title>
        <description>Number of participants died during study by Day 100 and reason for death was related to transplant.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Osteopetrosis Who Received Transplant</title>
            <description>All patients enrolled with osteopetrosis and received transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Transplant Related Death</title>
          <description>Number of participants died during study by Day 100 and reason for death was related to transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Transplant Related Toxicity</title>
        <description>Number of patients experiencing adverse effects due to transplant categorized by body system using Common Terminology Criteria for Adverse Events coding from the National Cancer Institute, Version 3.0.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Osteopetrosis Who Received Transplant</title>
            <description>All patients enrolled with osteopetrosis and received transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Transplant Related Toxicity</title>
          <description>Number of patients experiencing adverse effects due to transplant categorized by body system using Common Terminology Criteria for Adverse Events coding from the National Cancer Institute, Version 3.0.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neurologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-Transplant Mortality (Death by Day 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differential Imaging and Biologic Evaluations</title>
        <description>These outcome measures were not assessed due to early study termination.</description>
        <time_frame>Day 100, 6 months, 1, 2 and 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Osteopetrosis Who Received Transplant</title>
            <description>All patients enrolled with osteopetrosis and received transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Differential Imaging and Biologic Evaluations</title>
          <description>These outcome measures were not assessed due to early study termination.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Day 1 through Day 100 of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients With Osteopetrosis Who Received Transplant</title>
          <description>All patients enrolled with osteopetrosis and received transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death, peri-transplant</sub_title>
                <description>Death was related to receiving transplant.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 3 participants were treated in this study; all died by Day 100. Data for both treatment arms were combined due to low number. (Arm 1 utilized mobilized peripheral blood or marrow (related or unrelated). Arm 2 received cord blood transplants).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Orchard, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2313</phone>
      <email>orcha001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

